BPC-157 spenia to kryterium: rozwj kliniczny utkn na fazie II i nigdy nie uzyska rejestracji
Access, Cost and Shifting Landscape As people on these agents meet their weight and diabetes goals, there is concern that insurance companies will reduce or stop coverage given the high price tag of lifelong incretin therapy
Designing future trials In addition to a trial that studied a population at risk but without early-stage AD symptoms, Drucker also brought up additional factors that could have led to more positive trial results, including a different dose of semaglutide or another GLP-1 medicine that penetrates the brain better
CT-388, a biased dual GLP-1R/GIPR agonist, produced 4.78.0% body weight loss over 4 weeks in obese humans in Phase 1 (Chakravarthy et al., 2025)
Yet compared with eligible White individuals, larger proportions of Black and Hispanic individuals have potential barriers to GLP1 access, such as being uninsured, lacking a regular provider, having low income, or lacking higher education [239]
L- ,
